Shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation. Invivo Therapeutics’ rating score has improved by 50% from 90 days ago as a result of a number of analysts’ ratings changes.
Brokers have set a one year consensus price target of $118.75 for the company, according to Zacks. Zacks has also given Invivo Therapeutics an industry rank of 177 out of 255 based on the ratings given to its competitors.
Separately, ValuEngine upgraded Invivo Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 1st.
Invivo Therapeutics (NASDAQ:NVIV) last posted its quarterly earnings data on Monday, May 7th. The biotechnology company reported ($3.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.25) by ($0.09). analysts anticipate that Invivo Therapeutics will post -12.75 earnings per share for the current fiscal year.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.